Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
TERN-501 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| TERN-501 | DRUG | Investigational drug |
| TERN-101 | DRUG | Investigational drug |
| Placebo | OTHER | Matching placebo |
TERN-501 is an investigational small molecule being developed for the treatment of nonalcoholic steatohepatitis (NASH), a form of fatty liver disease. It is currently in Phase 2 clinical development and has been studied in noncirrhotic adults with presumed NASH.
TERN-501 is being developed by Terns Pharmaceuticals, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol TERN. The company is focused on developing therapies for metabolic diseases, including NASH.
TERN-501 is in Phase 2 clinical development. It has completed one Phase 2 trial, the DUET study, which evaluated the drug as a monotherapy and in combination with TERN-101 in patients with noncirrhotic NASH. It is not yet approved by regulatory authorities.
TERN-501 has been studied in the DUET study (NCT05415722), a Phase 2 clinical trial that evaluated the safety, efficacy, pharmacokinetics, and pharmacodynamics of orally administered TERN-501 as monotherapy and in combination with TERN-101 in noncirrhotic adults with presumed NASH. The trial enrolled 162 participants and has been completed.
No, TERN-501 and TERN-101 are different investigational drugs. TERN-501 was studied as a monotherapy and in combination with TERN-101 in the DUET trial, indicating they are distinct agents being developed by Terns Pharmaceuticals for NASH.